secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0001140361-23-012083
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Roivant Sciences appoints Meghan FitzGerald to board and Ilan Oren as Chairman
------------------------------------------------------------------------------

- Meghan M. FitzGerald appointed as Class II director and member of Nominating & Governance Committee, effective March 13, 2023.
- FitzGerald is a global healthcare strategist with experience at Cardinal Health, Pfizer, Sanofi, and adjunct professor at Columbia University.
- Board appointed Ilan Oren as Chairman; Oren has been a director since 2014 and Co-CEO of Dexcel Pharma.
- FitzGerald will receive cash and equity compensation per company's Non-Executive Director Compensation Policy; initial equity grant in April 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123012083/0001140361-23-012083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036123012083/brhc10049884_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-012083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer